

Article

Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study

Alexandra Moskalewicz, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley

Table S1: Frequency of self-reported gynecologic symptoms (GS) in the past year by endocrine therapy (ET) type.

Symptom	<i>n</i> ¹	Tamoxifen users (<i>n</i> , %)				<i>n</i> ¹	AI users (<i>n</i> , %)				<i>p</i> -value
		All the time	Often ²	Rarely ³	Never		All the time	Often ²	Rarely ³	Never	
Vaginal dryness	73	14 (19.2)	10 (13.7)	25 (34.2)	24 (32.9)	69	28 (40.6)	4 (5.8)	15 (21.7)	22 (31.9)	0.021
Vaginal discharge	75	15 (20.0)	21 (28.0)	16 (21.3)	23 (30.7)	66	2 (3.0)	6 (9.1)	15 (22.7)	43 (65.2)	<.001
Vaginal bleeding	71	1 (1.4)	1 (1.4)	14 (19.7)	55 (77.5)	66	1 (1.5)	0 (0.0)	7 (10.6)	58 (87.9)	0.266
Vaginal itchiness	72	2 (2.8)	10 (13.9)	23 (31.9)	37 (51.4)	65	3 (4.6)	6 (9.2)	22 (33.8)	34 (52.3)	0.821
Hot flashes/insomnia	75	34 (45.3)	14 (18.7)	22 (29.3)	5 (6.7)	66	29 (43.9)	18 (27.3)	8 (12.1)	11 (16.7)	0.027
Decreased sex drive	70	18 (25.7)	23 (32.9)	16 (22.9)	13 (18.6)	60	31 (51.7)	9 (15.0)	9 (15.0)	11 (18.3)	0.012
Feel depressed	69	8 (11.6)	15 (21.7)	25 (36.2)	21 (30.4)	63	6 (9.5)	20 (31.7)	13 (20.6)	24 (38.1)	0.193
		1 to 2	3 to 4	5 or more	None		1 to 2	3 to 4	5 or more	None	
Urinary tract infection (UTI)	69	5 (7.2)	2 (2.9)	0 (0.0)	62 (89.9)	66	7 (10.6)	2 (3.0)	3 (4.5)	54 (81.8)	0.338
Yeast infection/vaginitis	69	8 (11.6)	5 (7.2)	1 (1.4)	55 (79.7)	61	6 (9.8)	0 (0.0)	0 (0.0)	55 (90.2)	0.087

Abbreviations: AI (Aromatase inhibitor). ¹ *n* represents the number of breast cancer patients who responded to each question, of the total sample size of 151 patients. ² At least once a week. ³ A few times a year.

Table S2. FSFI domain and total scores by ET type.

FSFI domain	Tamoxifen users		AI users		<i>p</i> -value
	<i>n</i> ¹	Score (mean ± SD)	<i>n</i> ¹	Score (mean ± SD)	
Desire	35	3.02 ± 1.03	20	2.64 ± 1.24	0.188
Arousal	34	3.91 ± 1.17	20	3.50 ± 1.26	0.286
Lubrication	33	4.61 ± 1.50	20	4.13 ± 1.22	0.090
Orgasm	35	4.49 ± 1.11	20	4.18 ± 1.66	0.661
Satisfaction	32	4.68 ± 1.21	20	4.28 ± 1.44	0.308
Pain	32	4.63 ± 1.52	20	4.42 ± 1.81	1.000
Total score	29	24.89 ± 6.24	20	23.14 ± 6.51	0.334

Abbreviations: FSFI (Female Sexual Function Index). ¹ *n* indicates the number of breast cancer patients who completed the FSFI domain, of the total sample size of 55 sexually active patients who had one or more FSFI domain scored.

Table S3. MENQOL domain and total scores by ET type.

MENQOL domain	Tamoxifen users		AI users		<i>p</i> -value
	<i>n</i> ¹	Score (mean ± SD)	<i>n</i> ¹	Score (mean ± SD)	
Vasomotor	67	4.20 ± 2.32	62	4.03 ± 2.35	0.692
Psychosocial	62	3.50 ± 1.74	60	3.73 ± 1.84	0.525
Physical	56	3.56 ± 1.44	58	3.90 ± 1.76	0.357
Sexual	63	3.57 ± 2.11	56	4.26 ± 2.63	0.185
Total score	50	3.69 ± 1.48	48	4.06 ± 1.85	0.338

Abbreviations: MENQOL (Menopause-Specific Quality of Life questionnaire). ¹ *n* indicates the number of breast cancer patients who completed all items within a specific MENQOL domain for it to be scored, of the total sample size of 151 patients.